Ford JA, Liu X, Marshall AA, et al. - In this retrospective cohort study of cyclic citrullinated peptide (CCP)+ individuals observed at a US tertiary care system between 2009 and 2018 who were without RA or other systemic rheumatic diseases by medical record review at the time of CCP antibody positivity, experts examined the risk of progression to RA in people who were CCP antibody-positive without RA at primary presentation. A total of 340 CCP+ people who were without RA or other rheumatic diseases at baseline were recognized. Among CCP+ individuals without RA, the risk for progression to RA grew substantially with rising CCP antibody level. Thus, this study gives additional support for close monitoring for the development of RA among CCP+ people and recognizing approaches to alleviate this risk.